Search details
1.
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer.
Clin Cancer Res
; 14(1): 215-23, 2008 Jan 01.
Article
in English
| MEDLINE | ID: mdl-18172273
2.
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
J Clin Oncol
; 23(23): 5323-33, 2005 Aug 10.
Article
in English
| MEDLINE | ID: mdl-15939921
3.
Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.
J Clin Oncol
; 23(11): 2521-33, 2005 Apr 10.
Article
in English
| MEDLINE | ID: mdl-15710949
4.
Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing.
Eur J Cancer
; 42(2): 171-8, 2006 Jan.
Article
in English
| MEDLINE | ID: mdl-16406576
Results
1 -
4
de 4
1
Next >
>>